Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH treatment plan.

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

If you have MASH, GLP-1 medications may help treat the condition. Set yourself up for success with expert advice on diet, exercise, dose scheduling, and more.

Aviceda Therapeutics ("the Company" or "Aviceda"), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b ...

PureHealth Research today announced the launch of its new line of vein health supplements, offering a natural approach to supporting healthy circulation and promoting the appearance of ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...

Groundbreaking Harvard research reveals gut-produced molecules significantly influence obesity and blood sugar control. These ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...